Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:ENLV NASDAQ:KZR NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$4.15-2.9%$4.68$3.80▼$42.80$6.56M-1.29130,391 shs22,987 shsENLVEnlivex Therapeutics$1.13-1.3%$1.19$0.81▼$2.10$27.45M0.9250,653 shs157,017 shsKZRKezar Life Sciences$3.76-4.3%$3.94$3.56▼$9.18$27.54M0.6238,530 shs51,666 shsRNTXRein Therapeutics$1.24+4.3%$1.19$1.04▼$4.40$28.93M1.1475,075 shs50,452 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.93%0.00%+4.90%-56.19%-90.05%ENLVEnlivex Therapeutics+8.02%+13.37%+8.02%-2.97%-27.99%KZRKezar Life Sciences+0.26%+9.47%-3.44%-13.25%-50.72%RNTXRein Therapeutics0.00%+3.48%-10.53%-23.23%+118,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$4.15-2.9%$4.68$3.80▼$42.80$6.56M-1.29130,391 shs22,987 shsENLVEnlivex Therapeutics$1.13-1.3%$1.19$0.81▼$2.10$27.45M0.9250,653 shs157,017 shsKZRKezar Life Sciences$3.76-4.3%$3.94$3.56▼$9.18$27.54M0.6238,530 shs51,666 shsRNTXRein Therapeutics$1.24+4.3%$1.19$1.04▼$4.40$28.93M1.1475,075 shs50,452 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.93%0.00%+4.90%-56.19%-90.05%ENLVEnlivex Therapeutics+8.02%+13.37%+8.02%-2.97%-27.99%KZRKezar Life Sciences+0.26%+9.47%-3.44%-13.25%-50.72%RNTXRein Therapeutics0.00%+3.48%-10.53%-23.23%+118,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.00646.27% UpsideENLVEnlivex Therapeutics 2.33Hold$10.00784.96% UpsideKZRKezar Life Sciences 2.00Hold$9.00139.36% UpsideRNTXRein Therapeutics 2.00Hold$10.00705.87% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, KZR, ENLV, and RNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.009/27/2025ACXPAcurx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ENLVEnlivex TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KZRKezar Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RNTXRein TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.009/22/2025RNTXRein TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.009/22/2025RNTXRein TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.009/12/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.009/2/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/19/2025RNTXRein TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.63 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AKZRKezar Life SciencesN/AN/AN/AN/A$16.02 per shareN/ARNTXRein TherapeuticsN/AN/A$0.47 per share2.66$0.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$10.69N/AN/AN/AN/A-436.83%-192.25%11/11/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.58N/AN/AN/AN/A-58.31%-50.32%12/5/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)RNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/ALatest ACXP, KZR, ENLV, and RNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/A8/11/2025Q2 2025ACXPAcurx Pharmaceuticals-$2.00-$1.89+$0.11-$1.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.382.38ENLVEnlivex TherapeuticsN/A6.416.41KZRKezar Life Sciences0.037.297.29RNTXRein TherapeuticsN/A0.860.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%ENLVEnlivex Therapeutics1.02%KZRKezar Life Sciences67.90%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%ENLVEnlivex Therapeutics12.28%KZRKezar Life Sciences10.40%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals31.58 million1.26 millionOptionableENLVEnlivex Therapeutics7024.29 million21.31 millionOptionableKZRKezar Life Sciences607.32 million6.64 millionNot OptionableRNTXRein Therapeutics923.31 million22.12 millionN/AACXP, KZR, ENLV, and RNTX HeadlinesRecent News About These CompaniesRein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20October 1, 2025 | msn.comQ3 Earnings Estimate for RNTX Issued By HC WainwrightSeptember 26, 2025 | americanbankingnews.comHC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy RecommendationSeptember 22, 2025 | msn.comRein Therapeutics initiated with a Buy at H.C. WainwrightSeptember 22, 2025 | msn.comRein Therapeutics announces publication of data on LTI-03 in IPFSeptember 17, 2025 | msn.comRein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary FibrosisSeptember 17, 2025 | markets.businessinsider.comRein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary FibrosisSeptember 17, 2025 | globenewswire.comRein Therapeutics files to sell 10M shares of common stock for holdersSeptember 3, 2025 | msn.comBrookline Capital Downgrades Rein Therapeutics (RNTX)August 19, 2025 | msn.comRein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trialAugust 19, 2025 | msn.comRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisAugust 19, 2025 | globenewswire.comRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025August 14, 2025 | globenewswire.comXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationAugust 7, 2025 | finance.yahoo.comRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30, 2025 | finance.yahoo.comRNTX - Rein Therapeutics Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMRein Therapeutics Announces Adjournment of Annual Meeting of StockholdersJune 24, 2025 | prnewswire.comUS FDA puts on hold Rein Therapeutics' lung disease drug trialJune 12, 2025 | reuters.comRNTX Rein Therapeutics Inc.June 1, 2025 | seekingalpha.comRein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | finanznachrichten.deRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, KZR, ENLV, and RNTX Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$4.15 -0.13 (-2.94%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Enlivex Therapeutics NASDAQ:ENLV$1.13 -0.02 (-1.31%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Kezar Life Sciences NASDAQ:KZR$3.76 -0.17 (-4.33%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Rein Therapeutics NASDAQ:RNTX$1.24 +0.05 (+4.28%) As of 12:14 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
